These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 19193800)

  • 21. The N-linked glycan g15 within the V3 loop of the HIV-1 external glycoprotein gp120 affects coreceptor usage, cellular tropism, and neutralization.
    Polzer S; Dittmar MT; Schmitz H; Schreiber M
    Virology; 2002 Dec; 304(1):70-80. PubMed ID: 12490404
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adaptive mutations in the V3 loop of gp120 enhance fusogenicity of human immunodeficiency virus type 1 and enable use of a CCR5 coreceptor that lacks the amino-terminal sulfated region.
    Platt EJ; Kuhmann SE; Rose PP; Kabat D
    J Virol; 2001 Dec; 75(24):12266-78. PubMed ID: 11711617
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of naturally occurring basic amino acid substitutions in the human immunodeficiency virus type 1 subtype E envelope V3 loop on viral coreceptor usage and cell tropism.
    Kato K; Sato H; Takebe Y
    J Virol; 1999 Jul; 73(7):5520-6. PubMed ID: 10364300
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Viral entry as therapeutic target. Current situation of entry inhibitors].
    Arenzana-Seisdedos F
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():5-11. PubMed ID: 19133215
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potent synergistic anti-human immunodeficiency virus (HIV) effects using combinations of the CCR5 inhibitor aplaviroc with other anti-HIV drugs.
    Nakata H; Steinberg SM; Koh Y; Maeda K; Takaoka Y; Tamamura H; Fujii N; Mitsuya H
    Antimicrob Agents Chemother; 2008 Jun; 52(6):2111-9. PubMed ID: 18378711
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tissue-specific sequence alterations in the human immunodeficiency virus type 1 envelope favoring CCR5 usage contribute to persistence of dual-tropic virus in the brain.
    Gray L; Roche M; Churchill MJ; Sterjovski J; Ellett A; Poumbourios P; Sherieff S; Wang B; Saksena N; Purcell DF; Wesselingh S; Cunningham AL; Brew BJ; Gabuzda D; Gorry PR
    J Virol; 2009 Jun; 83(11):5430-41. PubMed ID: 19321618
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The V1-V3 region of a brain-derived HIV-1 envelope glycoprotein determines macrophage tropism, low CD4 dependence, increased fusogenicity and altered sensitivity to entry inhibitors.
    Rossi F; Querido B; Nimmagadda M; Cocklin S; Navas-Martín S; Martín-García J
    Retrovirology; 2008 Oct; 5():89. PubMed ID: 18837996
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A low-molecular-weight entry inhibitor of both CCR5- and CXCR4-tropic strains of human immunodeficiency virus type 1 targets a novel site on gp41.
    Murray EJ; Leaman DP; Pawa N; Perkins H; Pickford C; Perros M; Zwick MB; Butler SL
    J Virol; 2010 Jul; 84(14):7288-99. PubMed ID: 20427524
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure and dynamics of the gp120 V3 loop that confers noncompetitive resistance in R5 HIV-1(JR-FL) to maraviroc.
    Yuan Y; Yokoyama M; Maeda Y; Terasawa H; Harada S; Sato H; Yusa K
    PLoS One; 2013; 8(6):e65115. PubMed ID: 23840315
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors; overview of viral entry inhibition.
    Panos G; Watson DC
    Crit Rev Microbiol; 2015; 41(4):473-87. PubMed ID: 24635642
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of HIV-1 entry inhibitors with broad activity against R5 and X4 viral strains.
    Sironi F; Malnati M; Mongelli N; Cozzi P; Guzzo C; Ghezzi S; Martínez-Romero C; García-Sastre A; Lusso P; Jabes D; Biswas P
    J Transl Med; 2015 Apr; 13():107. PubMed ID: 25888743
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug.
    Putcharoen O; Lee SH; Henrich TJ; Hu Z; Vanichanan J; Coakley E; Greaves W; Gulick RM; Kuritzkes DR; Tsibris AM
    J Virol; 2012 Jan; 86(2):1119-28. PubMed ID: 22090117
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less-efficient mechanism of gp120-CCR5 engagement that attenuates macrophage tropism.
    Roche M; Jakobsen MR; Sterjovski J; Ellett A; Posta F; Lee B; Jubb B; Westby M; Lewin SR; Ramsland PA; Churchill MJ; Gorry PR
    J Virol; 2011 May; 85(9):4330-42. PubMed ID: 21345957
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Presence of HIV-1 R5 viruses in cerebrospinal fluid even in patients harboring R5X4/X4 viruses in plasma.
    Soulié C; Tubiana R; Simon A; Lambert-Niclot S; Malet I; Canestri A; Brunet C; Murphy R; Katlama C; Calvez V; Marcelin AG
    J Acquir Immune Defic Syndr; 2009 May; 51(1):60-4. PubMed ID: 19390328
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5.
    Tilton JC; Wilen CB; Didigu CA; Sinha R; Harrison JE; Agrawal-Gamse C; Henning EA; Bushman FD; Martin JN; Deeks SG; Doms RW
    J Virol; 2010 Oct; 84(20):10863-76. PubMed ID: 20702642
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Functional impact of HIV coreceptor-binding site mutations.
    Biscone MJ; Miamidian JL; Muchiri JM; Baik SS; Lee FH; Doms RW; Reeves JD
    Virology; 2006 Jul; 351(1):226-36. PubMed ID: 16631222
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiple CCR5 conformations on the cell surface are used differentially by human immunodeficiency viruses resistant or sensitive to CCR5 inhibitors.
    Berro R; Klasse PJ; Lascano D; Flegler A; Nagashima KA; Sanders RW; Sakmar TP; Hope TJ; Moore JP
    J Virol; 2011 Aug; 85(16):8227-40. PubMed ID: 21680525
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus.
    Platt EJ; Durnin JP; Kabat D
    J Virol; 2005 Apr; 79(7):4347-56. PubMed ID: 15767435
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of V3 independent domains on a dualtropic human immunodeficiency virus type 1 (HIV-1) envelope gp120 in CCR5 coreceptor utilization and viral infectivity.
    Foda M; Harada S; Maeda Y
    Microbiol Immunol; 2001; 45(7):521-30. PubMed ID: 11529558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro.
    Svicher V; Balestra E; Cento V; Sarmati L; Dori L; Vandenbroucke I; D'Arrigo R; Buonomini AR; Van Marck H; Surdo M; Saccomandi P; Mostmans W; Aerssens J; Aquaro S; Stuyver LJ; Andreoni M; Ceccherini-Silberstein F; Perno CF
    Antiviral Res; 2011 Apr; 90(1):42-53. PubMed ID: 21349294
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.